AbbVie (ABBV) Given a $84.00 Price Target at BMO Capital Markets
ABBV has been the topic of several other reports. Leerink Swann set a $106.00 price objective on AbbVie and gave the company a buy rating in a report on Tuesday, December 5th. Argus raised their price objective on AbbVie from $90.00 to $110.00 and gave the company a buy rating in a report on Friday, September 29th. UBS Group lowered AbbVie from a buy rating to a neutral rating and raised their price objective for the company from $79.00 to $92.00 in a report on Monday, September 25th. SunTrust Banks reissued a buy rating and issued a $95.00 price objective on shares of AbbVie in a report on Wednesday, September 13th. Finally, Piper Jaffray Companies reaffirmed a buy rating and issued a $100.00 price target on shares of AbbVie in a research note on Friday, September 15th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $100.94.
Shares of AbbVie (ABBV) opened at $100.34 on Thursday. The company has a market capitalization of $160,185.78, a PE ratio of 24.41, a P/E/G ratio of 1.20 and a beta of 1.52. AbbVie has a 1-year low of $59.27 and a 1-year high of $101.28. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08.
The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be paid a $0.71 dividend. The ex-dividend date of this dividend is Thursday, January 11th. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.83%. AbbVie’s payout ratio is currently 69.10%.
In related news, insider Henry O. Gosebruch sold 18,300 shares of AbbVie stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the transaction, the insider now owns 81,287 shares in the company, valued at $7,360,537.85. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Timothy J. Richmond sold 87,040 shares of AbbVie stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $98.45, for a total value of $8,569,088.00. Following the transaction, the senior vice president now owns 113,118 shares in the company, valued at approximately $11,136,467.10. The disclosure for this sale can be found here. Insiders sold 494,676 shares of company stock worth $47,237,938 over the last ninety days. Corporate insiders own 0.23% of the company’s stock.
A number of institutional investors have recently made changes to their positions in ABBV. Bristlecone Advisors LLC purchased a new stake in AbbVie in the third quarter valued at $113,000. Acropolis Investment Management LLC purchased a new stake in AbbVie in the second quarter valued at $106,000. Ffcm LLC raised its position in AbbVie by 167.2% in the second quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after purchasing an additional 963 shares during the period. Hudock Capital Group LLC raised its position in AbbVie by 109.5% in the second quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock valued at $111,000 after purchasing an additional 806 shares during the period. Finally, Hershey Trust Co. purchased a new stake in AbbVie in the third quarter valued at $139,000. Hedge funds and other institutional investors own 69.19% of the company’s stock.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Stock Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related stocks with our FREE daily email newsletter.